A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A study for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) using study drug SY-1425
Sponsor: Syros Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAQ8613
U.S. Govt. ID: NCT02807558
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is being done to determine if an investigational drug, SY-1425 (tamibarotene) works in treating AML (acute myeloid leukemia) and MDS (myelodysplastic syndrome) in patients with a certain biomarker in their blood (a blood test that may indicate the drug target is present in your type of AML or MDS).
This study is closed
Joseph Jurcic, MD
Do You Qualify?
Have you been diagnosed with MDS or AML? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator